Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis

Neurology

Volumn 50, Issue 1, 1998, Pages 62-66

  Gurney, Mark E ^a   Fleck, Timothy J ^a   Himes, Carol S ^a   Hall, Edward D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FAMILIAL DISEASE; GENE MUTATION; MOTONEURON; MOTOR PERFORMANCE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SURVIVAL; TRANSGENIC MOUSE;

EID: 0031931578     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.1.62     Document Type: Article

References (14)

1. Siddique T, Figlewicz DA, Pericak-Vance MA, et al. Linkage of a gêné causing familial amyotrophic- lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med 1991;324:1381-1384.
2. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu.Zn Superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
3. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn Superoxide dismutase mutation. Science 1994;264:1772-1775.
4. Rothstein JD. Excitotoxic mechanism in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995;68:2-20.
5. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
6. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Doseranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
7. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993; 250:473-476.
8. Debono MW, Le Guern J, Canton T, Doble A, Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993;235:283-289.
9. Stutzmann JM, Doble A. Blockage of glutamatergic transmission and neuroprotection: the strange case of riluzole. In: Jolies G, Stutzmann JM, eds. Neurodegenerative diseases. Academic Press, 1994:205-214.
10. Mantz J, Laudenbach V, Lechamy J-B, Henzel D, Desmonts J-M. Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes. Eur J Pharmacol 1994;257:R7-R8.
11. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147157.
12. Mizoule J. Medicament based on 2-amino-6-trifluromethoxybenzothiazole. US Patent 4,370,338; 1993.
13. Chiu AY, Zhai P, Dal Canto MC, et al. Age dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci 1995;6:349362.
14. Mitsumoto H. Riluzole: what is its impact in our treatment and understanding of amyotrophic lateral sclerosis? Ann Pharmacother 1997;31:779-781.